Edasalonexent

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

Edasalonexent (CAT-1004) 是一种双功能口服小分子，共价连接 2 种已知可抑制 NF-κB 的化合物：水杨酸和二十二碳六烯酸 (DHA)。

Edasalonexent (CAT-1004) is a bifunctional, orally administered small molecule that covalently links 2 compounds known to inhibit NF‐κB, salicylic acid and docosahexaenoic acid (DHA); significantly inhibits NF-κB p65-dependent inflammatory responses as well as downstream proinflammatory genes modulated by p65 in the golden retriever DMD model; Edasalonexent is hydrolyzed by FAAH to release salicylic acid and DHA intracellularly and to suppress activated NF-κB.Other Indication Phase 2 Clinical.

Edasalonexent is an orally administered small molecule in which salicylic acid and docosahexaenoic acid (DHA) are covalently conjugated through an ethylenediamine linker and that is designed to synergistically leverage the ability of both of these compounds to inhibit NF-κB. Edasalonexent significantly inhibits NF-κB p65-dependent inflammatory responses as well as downstream proinflammatory genes modulated by p65 in the golden retrieverduchenne muscular dystrophy (DMD) model.

The treatment of mdx mice with Edasalonexent for 20 weeks results in reduced susceptibility of the extensor digitorum longus muscle to eccentric contraction-induced injury.

CAT-1004 | CAT1004

Apoptosis

NF-κB

NF-κB

Other Indications

Other Disease

1204317-86-1

490.688

C31H42N2O3

>98% (HPLC)

In Vitro:?DMSO : 120 mg/mL (244.56 mM)

O=C(NCCNC(CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CC)=O)C1=CC=CC=C1O

N-[2-[[(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoyl]amino]ethyl]-2-hydroxybenzamide

(-20℃)

With Ice Pack

≥ 2 years